SSHPF yields 926.35% · PFE yields 6.13%● Live data
📍 SSHPF pulled ahead of the other in Year 1
Combined, SSHPF + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SSHPF + PFE for your $10,000?
Vow ASA, together with its subsidiaries, produces, delivers, and maintains systems for processing and purifying wastewater, food waste, solid waste, and bio sludge in Norway, France, Poland, the United States, Canada, and Italy. It operates in three segments: Projects Cruise, Aftersales, and Landbased. The Projects Cruise segment delivers ship systems to shipyards for newbuild constructions, which include advanced wastewater purification, waste management, and food waste processing; advanced systems to shipowners for ships; and systems for aquaculture sludge treatment. The Aftersales segment provides spare parts and consumables; chemicals; and tailor-made service and maintenance programs. The Landbased segment offers Biogreen, a patented pyrolysis process for converting biomass, plastics, and waste into energy; Safesteril, a patented sterilisation process for food and pharmaceutical ingredients; and industrial robotics solutions, including robotic systems for waste recycling processes. The company serves cruise, aquaculture, and landbased industries, as well as utilities. It has a strategic partnership agreement with Repsol, S.A. to explore applications and solutions to produce clean and renewable energy for CO2 emission reduction. The company was formerly known as Scanship Holding ASA and changed its name to VOW ASA in January 2020. Vow ASA was incorporated in 2011 and is headquartered in Lysaker, Norway.
Full SSHPF Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.